FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

9 letters match. Newest first.

  1. Tides Medical LLC

    FDA warns Tides Medical over APLICOR 3D wound device sold without approval, exemption, or required FDA notice.

    High risk
  2. Microvascular Tissue, Inc.

    FDA says Microvascular Tissue's mVASC wound product is an unapproved drug and unlicensed biologic, made without validated processes.

    High risk
  3. BioXtek LLC

    FDA says BioXtek's amniotic membrane products are unapproved new drugs and unlicensed biological products.

    High risk
  4. DermaRite Industries, LLC

    DermaRite failed CGMP and sold unapproved, misbranded OTC topical drugs, FDA says.

    High risk
  5. Qianjiang Kingphar Medical Material Co Ltd.

    FDA warned Chinese device maker Qianjiang Kingphar that dirty cleanrooms and weak environmental controls make its masks, dressings, wraps and drapes adulterated.

    High risk
  6. The Richline Group, Inc.

    FDA warns Richline Group over unapproved Inverness ear care products and quality-system failures.

    High risk
  7. NuVida Medical LLC

    FDA says NuVida Medical sells unapproved, unlicensed tissue products for non-homologous wound care uses.

    High risk
  8. AG Essence, Inc.

    FDA warned AG Essence that its Banda-SiL silver wound gels are adulterated and misbranded because they are sold without required FDA marketing clearance.

    High risk
  9. Integra LifeSciences Corporation

    FDA warned Integra LifeSciences over collagen-based medical devices made in Boston after an inspection found quality-system failures and endotoxin testing problems.

    High risk